Sign in
CompletedPhase 4

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Key facts

Who runs it
Duke University
Where
Atlanta, Cleveland, Phoenix, Pittsburgh, South Euclid, St Louis, and Tempe, United StatesSee the 8 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
455 people enrolled
Started
25 Sept 2023
Ended
17 May 2024
Type of study
Interventional, 3 groups
Treatments tested
  • Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
  • Sequential Vaccination (Influenza vaccine then mRNA COVID booster)
  • Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Record updated
13 June 2025

Who can take part

Age
6 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Healthy children aged 6-11 years and healthy adults aged 18-64 years that have not received the current season's influenza vaccination or a mRNA COVID-19 vaccination in the past 6 months and have already completed at least a two-dose primary series of an mRNA COVID-19 vaccination
  • English or Spanish literate
  • Email or text message capability for weekly follow-up
  • Intention of receiving influenza vaccine and mRNA COVID-19 vaccine based on ACIP-CDC guidelines
  • Willing to provide written/electronic informed consent
  • Intention of being available for entire study period and able to complete all relevant study procedures, including follow-up phone calls and clinic visits

Who cannot take part

  • Self-reported COVID-19 infection within 3 months prior to enrollment
  • Received COVID-19 vaccine within 6 months prior to enrollment
  • Received influenza vaccine during the respective influenza season in which the participants are being enrolled
  • History of severe allergic reaction after a previous dose of any influenza or COVID-19 mRNA vaccine; or to an influenza or COVID-19 mRNA vaccine component
  • Receipt of any licensed vaccine within 6 weeks prior to enrollment in this study or planning receipt of any vaccines within 4 weeks after the receipt of the second vaccine dose administered during study procedures
  • Has an immunocompromising condition or taking immunosuppressive medication*; Received oral, intramuscular or intravenous systemic immunosuppressants, or immune modifying drugs for >14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg/day of prednisone equivalent); ** Note: Topical medications are allowed
  • Received immunoglobulin, SARS-CoV-2 immunoglobulin, SARS-CoV-2 monoclonal antibody, or blood-derived products, within 3 months prior any study vaccine dose
  • Temporary Delay Criteria: History of febrile illness (> 100.0°F or 37.8°C) within the past 72 hours prior to vaccine administration
  • History of Guillain-Barré syndrome
  • History of myocarditis or pericarditis
  • History of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A)
  • Bleeding disorder diagnosed by a healthcare provider or bleeding difficulties with intramuscular injections or blood draws
  • Any condition which, in the opinion of the investigators, may pose a health risk to the participant or interfere with the evaluation of the study objectives
  • < 9 years of age and recommended to receive two doses of IIV4 during the respective influenza season in which they are being enrolled
  • Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report or likely to be pregnant per screening criteria
  • Has injury or other reason why deltoid site on both arms cannot be used for vaccinations

Where in United States

  • Centers for Disease Control and PreventionAtlanta, United States
  • University Hospitals Cleveland Medical Center*Cleveland, United States
  • VA Northeast Ohio Healthcare System (VANEOHS)Cleveland, United States
  • Valleywise Health Comprehensive Health CenterPhoenix, United States
  • Department of Family Medicine, University of Pittsburgh School of MedicinePittsburgh, United States
  • Senders PediatricsSouth Euclid, United States
  • Washington University IDCRUSt Louis, United States
  • ASU Biodesign InstituteTempe, United States

About the trial

What the trial wants to find out

This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.

The 3 groups in the trial

  • Group i: Concomitant VaccinationTreatment being tested

    Concomitant Vaccination (Influenza vaccine and mRNA COVID booster) at Visit 1

    Treatment: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)

  • Group ii: Influenza Vaccination at Visit 1Treatment being tested

    Sequential vaccination with Influenza vaccination at Visit 1 and mRNA COVID booster at Visit 2

    Treatment: Sequential Vaccination (Influenza vaccine then mRNA COVID booster)

  • Group iii: mRNA COVID-19 Vaccination at Visit 1Treatment being tested

    Sequential vaccination with mRNA COVID booster at Visit 1 and Influenza vaccination at Visit 2

    Treatment: Sequential Vaccination (mRNA COVID booster then Influenza vaccine)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults
Record updated
13 June 2025